Evidence map›Paper›PMID 40571744›Full record

ArticleLeukemia2025

DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT.

Francesca Grassi, Madhurendra Singh, Simon Moussaud, Gabriela Vazquez Rodriguez, Zaheer Ali, Kirsten Janssen, Mathilde Cheray, Elory Leonard, Martin Andersson, Angelo de Milito and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesca GrassiSprint Bioscience AB, Huddinge, Sweden.
Madhurendra SinghSprint Bioscience AB, Huddinge, Sweden.ORCID http://orcid.org/0000-0001-9935-5706
Simon MoussaudSprint Bioscience AB, Huddinge, Sweden.ORCID http://orcid.org/0000-0002-6340-9511
Gabriela Vazquez RodriguezBioReperia AB, Linköping, Sweden.ORCID http://orcid.org/0000-0001-9310-2433
Zaheer AliBioReperia AB, Linköping, Sweden.
Kirsten JanssenSprint Bioscience AB, Huddinge, Sweden.ORCID http://orcid.org/0000-0003-3728-8530
Mathilde CheraySprint Bioscience AB, Huddinge, Sweden.ORCID http://orcid.org/0000-0002-7551-6357
Elory LeonardDepartment of Medicine Huddinge, Centre for Haematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
Martin AnderssonSprint Bioscience AB, Huddinge, Sweden.ORCID http://orcid.org/0009-0001-5999-5482
Angelo de MilitoSprint Bioscience AB, Huddinge, Sweden.ORCID http://orcid.org/0000-0003-2591-2914
Hong QianDepartment of Medicine Huddinge, Centre for Haematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-2512-9199
Julian WalfridssonDepartment of Medicine Huddinge, Centre for Haematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
Andreas HöglundSprint Bioscience AB, Huddinge, Sweden. andreas.hoglund@sprintbioscience.com.ORCID http://orcid.org/0009-0003-1308-6544

Funding

Stiftelsen för Strategisk Forskning (Swedish Foundation for Strategic Research) ID21-0048
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40571744
PMCPMC12310507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.